Discover undervalued stocks with Eulerpool.

Subscribe for $2

Sorrento Therapeutics Stock SRNE

Price

0
Today +/-
-0
Today %
-0 %

Sorrento Therapeutics stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Sorrento Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Sorrento Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Sorrento Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Sorrento Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Sorrento Therapeutics Stock Price History

DateSorrento Therapeutics Price
9/24/20250 undefined
9/23/20250.00 undefined
9/22/20250.01 undefined
9/22/20250.00 undefined
9/19/20250.01 undefined
9/18/20250.01 undefined
9/17/20250.01 undefined
9/16/20250.01 undefined
9/15/20250.00 undefined
9/12/20250.00 undefined
9/11/20250.00 undefined
9/10/20250.00 undefined
9/9/20250.00 undefined
9/8/20250.00 undefined
9/5/20250.00 undefined
9/4/20250.00 undefined
9/3/20250.01 undefined
9/2/20250.01 undefined
8/29/20250.01 undefined
8/28/20250.01 undefined
8/27/20250.01 undefined

Sorrento Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sorrento Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sorrento Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sorrento Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sorrento Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sorrento Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sorrento Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sorrento Therapeutics’s growth potential.

Sorrento Therapeutics Revenue, EBIT and net profit per share

DateSorrento Therapeutics RevenueSorrento Therapeutics EBITSorrento Therapeutics Net Income
2026e25.45 B undefined15.13 B undefined16.01 B undefined
2025e416.02 M undefined48.68 M undefined34.21 M undefined
2024e214.86 M undefined-178.27 M undefined-141.14 M undefined
2023e58.68 M undefined-358.14 M undefined-290.83 M undefined
202262.8 M undefined-315.4 M undefined-572.8 M undefined
202152.9 M undefined-401.4 M undefined-428.3 M undefined
202040 M undefined-244.6 M undefined-298.5 M undefined
201931.4 M undefined-259.4 M undefined-292.1 M undefined
201821.2 M undefined-150.4 M undefined-203.5 M undefined
2017151.9 M undefined25.4 M undefined9.1 M undefined
20168.2 M undefined-96.8 M undefined-60.9 M undefined
20154.6 M undefined-74 M undefined-45.8 M undefined
20143.8 M undefined-34.7 M undefined-34.7 M undefined
2013500,000 undefined-21.7 M undefined-21.9 M undefined
2012600,000 undefined-4.9 M undefined-4.8 M undefined
2011500,000 undefined-3.2 M undefined-3.2 M undefined
2010700,000 undefined-1.8 M undefined-1.8 M undefined
20090 undefined-1 M undefined-900,000 undefined
20080 undefined0 undefined0 undefined
20070 undefined-200,000 undefined-300,000 undefined
20060 undefined-400,000 undefined-400,000 undefined
20050 undefined0 undefined300,000 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined

Sorrento Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (B)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e
00000000000000.010.150.020.030.040.050.060.060.210.4225.45
------------33.33100.001,787.50-86.0947.6229.0330.0019.23-6.45268.9794.396,016.83
-----------33.3350.0087.5097.3566.6761.2975.0075.0046.7750.0013.556.970.11
0000000000012714714193039290000
0000000-0-0-0-0.02-0.03-0.05-0.060.01-0.2-0.29-0.3-0.43-0.57-0.29-0.140.0316.01
--------200.0033.33425.0061.9032.3533.33-115.00-2,355.5643.842.0543.6233.64-49.30-51.38-124.1146,994.12
0.30.30.30.30.34.16.18.89.911.41526.736.950.470.4106.2132.7229.8294.8419.30000
- - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Sorrento Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Sorrento Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (k)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20032004200520062007200820092010201120122013201420152016201720182019202020212022
                                       
0000003.45.33.55.131.771.9136.483.520.915922.556.5126.950
00000000.20.10.10.40.70.91.72.23.814.515.518.724.5
0000000000001.71.31.70.60000
00000000000000003.41.88.110
0000000000.10.61.323.24.916.227.212.419.311.9
0000003.45.53.65.332.773.914189.729.7179.667.686.217396.4
0000000.10.111.52.42.37.212.719.324.476.373.9126.5138.4
0000000000010170.1189270265262.2256.451.317.2
00000000000000000000
000000000033.34.43.964.87166.363.373.7259.7136.9
00000000002412.520.641.538.338.338.343.679.580.3
00000000000.138.50.63.93.350.649.924.83.7
0000000.10.111.559.867.7202.4311.9401.9444.6490449.6521.8376.5
0000003.55.64.66.892.5141.6343.4401.6431.6624.2557.6535.8694.8472.9
                                       
0000000000000000000100
00000000.010.010.020.10.180.180.30.410.630.791.171.511.99
-1.1-1.1-0.8-1.2-1.5-0.1-1.1-2.9-6.1-11-32.9-67.5-113.3-174.3-165.1-367.8-659.8-958.3-1,386.6-1,959.4
00000000000073.6-0.10.20-0.30.511.5
00000000000000000000
-0.4-0.4-0.1-0.50-0.13.154.26.166.8108.7145.2129.5249258.9128214.5128.231
0.10.100.500.10.30.20.20.42.21.71.38.39.913.827.624.727.447.5
0.20.2000000.20.10.122.76.38.311.823.63843.771255.3
00000000.2000.91.918.459.357.31413.44.998.8
00000000000000000000
00000000000.43.34.80.2010.236.323.23216.3
0.30.300.500.10.30.60.30.55.59.630.876.17961.6115.396.5139.4327.9
00000000004.48.84.447.15.2223.1199.192.3110.619.1
000000000014.21.749.353.215.59.496.92.40.6
00000000001.612.7118138.7125.3122.4201.5199.4364.2146.9
000000000020.223.2171.7239146354.9409.6298.6477.2166.6
0.30.300.500.10.30.60.30.525.732.8202.5315.1225416.5524.9395.1616.6494.5
-0.1-0.1-0.10003.45.64.56.692.5141.5347.7444.6474675.4652.9609.6744.8525.5
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Sorrento Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Sorrento Therapeutics's financial health and stability.

Assets

Sorrento Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Sorrento Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Sorrento Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Sorrento Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)

Sorrento Therapeutics stock margins

The Sorrento Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sorrento Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sorrento Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sorrento Therapeutics's sales revenue. A higher gross margin percentage indicates that the Sorrento Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sorrento Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sorrento Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sorrento Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sorrento Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sorrento Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sorrento Therapeutics Margin History

Sorrento Therapeutics Gross marginSorrento Therapeutics Profit marginSorrento Therapeutics EBIT marginSorrento Therapeutics Profit margin
2026e46.82 %59.48 %62.92 %
2025e46.82 %11.7 %8.22 %
2024e46.82 %-82.97 %-65.69 %
2023e46.82 %-610.34 %-495.63 %
202246.82 %-502.23 %-912.1 %
202175.43 %-758.79 %-809.64 %
202075 %-611.5 %-746.25 %
201961.15 %-826.11 %-930.25 %
201866.51 %-709.43 %-959.91 %
201797.37 %16.72 %5.99 %
201689.02 %-1,180.49 %-742.68 %
201556.52 %-1,608.7 %-995.65 %
201447.37 %-913.16 %-913.16 %
2013100 %-4,340 %-4,380 %
201246.82 %-816.67 %-800 %
201146.82 %-640 %-640 %
201046.82 %-257.14 %-257.14 %
200946.82 %0 %0 %
200846.82 %0 %0 %
200746.82 %0 %0 %
200646.82 %0 %0 %
200546.82 %0 %0 %
200446.82 %0 %0 %
200346.82 %0 %0 %

Sorrento Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Sorrento Therapeutics earnings per share therefore indicates how much revenue Sorrento Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sorrento Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sorrento Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sorrento Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sorrento Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sorrento Therapeutics Revenue, EBIT and net profit per share

DateSorrento Therapeutics Sales per ShareSorrento Therapeutics EBIT per shareSorrento Therapeutics Earnings per Share
2026e60.69 undefined0 undefined38.19 undefined
2025e0.99 undefined0 undefined0.08 undefined
2024e0.51 undefined0 undefined-0.34 undefined
2023e0.14 undefined0 undefined-0.69 undefined
20220.15 undefined-0.75 undefined-1.37 undefined
20210.18 undefined-1.36 undefined-1.45 undefined
20200.17 undefined-1.06 undefined-1.3 undefined
20190.24 undefined-1.95 undefined-2.2 undefined
20180.2 undefined-1.42 undefined-1.92 undefined
20172.16 undefined0.36 undefined0.13 undefined
20160.16 undefined-1.92 undefined-1.21 undefined
20150.12 undefined-2.01 undefined-1.24 undefined
20140.14 undefined-1.3 undefined-1.3 undefined
20130.03 undefined-1.45 undefined-1.46 undefined
20120.05 undefined-0.43 undefined-0.42 undefined
20110.05 undefined-0.32 undefined-0.32 undefined
20100.08 undefined-0.2 undefined-0.2 undefined
20090 undefined-0.16 undefined-0.15 undefined
20080 undefined0 undefined0 undefined
20070 undefined-0.67 undefined-1 undefined
20060 undefined-1.33 undefined-1.33 undefined
20050 undefined0 undefined1 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined

Sorrento Therapeutics business model

Sorrento Therapeutics is a biotechnology company based in San Diego, California. It was founded in 2006 by Dr. Henry Ji and specializes in the research and development of biopharmaceuticals, particularly in the field of oncology. Sorrento Therapeutics is one of the most popular companies on Eulerpool.com.

Sorrento Therapeutics SWOT Analysis

Strengths

Sorrento Therapeutics Inc possesses several strengths that contribute to its success and competitiveness in the market:

  • Strong and diverse portfolio of innovative biopharmaceutical products
  • Significant expertise in antibody-centric development and immunotherapies
  • Robust research and development capabilities, fostering continuous innovation
  • Strong intellectual property rights and patent portfolio
  • Strategic collaborations and partnerships with leading industry players

Weaknesses

Despite its strengths, Sorrento Therapeutics Inc also faces certain weaknesses that could hinder its growth:

  • Reliance on external funding for research and product development
  • Limited market presence and brand recognition compared to larger competitors
  • Potential vulnerability to changes in government regulations and healthcare policies
  • Risk of product-related setbacks and delays in clinical trials

Opportunities

Sorrento Therapeutics Inc can explore the following opportunities to further expand its business:

  • Growing demand for innovative biopharmaceutical products globally
  • Expansion into new therapeutic areas and target indications
  • Potential for strategic acquisitions to enhance product portfolio and capabilities
  • Participation in government-sponsored research and development initiatives
  • Collaboration with academic institutions to access novel technologies and expertise

Threats

Sorrento Therapeutics Inc should be cautious of the following threats that could affect its business:

  • Intense competition within the biopharmaceutical industry
  • Rapidly evolving regulatory environment and potential pricing pressures
  • Potential risks associated with intellectual property infringement
  • Uncertainties related to the success and market acceptance of new product launches
  • Global economic downturns and fluctuations in healthcare spending
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Sorrento Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Sorrento Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Sorrento Therapeutics shares outstanding

The number of shares was Sorrento Therapeutics in 2024 — This indicates how many shares 419.3 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sorrento Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sorrento Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sorrento Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sorrento Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sorrento Therapeutics stock splits

In Sorrento Therapeutics's history, there have been no stock splits.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Sorrento Therapeutics.

Sorrento Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2023-0.16 -0.26  (-59.31 %)2023 Q1
12/31/2022-0.19 -0.46  (-138.26 %)2022 Q4
9/30/2022-0.26 -0.2  (23.11 %)2022 Q3
6/30/2022-0.26 -0.54  (-111.76 %)2022 Q2
12/31/2021-0.3 -0.47  (-56.2 %)2021 Q4
9/30/2021-0.23 -0.4  (-70.5 %)2021 Q3
6/30/2021-0.2 -0.57  (-179.41 %)2021 Q2
3/31/20210.38 0.01  (-97.4 %)2021 Q1
12/31/20202.77 -0.27  (-109.75 %)2020 Q4
9/30/2020-0.21 -0.33  (-57.82 %)2020 Q3
1
2
3
4

Eulerpool ESG Scorecard© for the Sorrento Therapeutics stock

Eulerpool World ESG Rating (EESG©)

59/ 100

🌱 Environment

59

👫 Social

95

🏛️ Governance

23

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sorrento Therapeutics shareholders

%
Name
Stocks
Change
Date
0.02623 % Swisspartners Investment Network AG110,00006/30/2024
0.01341 % State Street Global Advisors (US)56,245012/31/2023
0.01078 % BlackRock Institutional Trust Company, N.A.45,19603/31/2025
0.00119 % Huntington Private Financial Group5,00106/30/2025
0.00083 % Guggenheim Investments3,48105/31/2025
0.00029 % Highlander Capital Management, LLC1,20003/31/2024
0.00000 % Financial Gravity Asset Management, Inc.1806/30/2025
0 % SlateStone Wealth, LLC0-21,43312/31/2024
0 % HighPoint Advisor Group, LLC0-22,2503/31/2025
0 % Ogorek Wealth Management, LLC0-1,4793/31/2025
1
2

Sorrento Therapeutics Executives and Management Board

Dr. Henry Ji

(58)
Sorrento Therapeutics Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer (since 2006)
Compensation 10.07 M

Mr. Jaisim Shah

(63)
Sorrento Therapeutics Director
Compensation 868,233

Mr. Dorman Followwill

(59)
Sorrento Therapeutics Lead Independent Director
Compensation 250,018

Mr. David Lemus

(60)
Sorrento Therapeutics Independent Director
Compensation 181,326

Dr. Yue Wu

(59)
Sorrento Therapeutics Independent Director
Compensation 150,000
1
2

Sorrento Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
ITOCHU Stock
ITOCHU
SupplierCustomer0,370,57-0,38-0,90-0,87-0,53
Lee's Pharm Stock
Lee's Pharm
SupplierCustomer-0,300,770,830,880,940,75
Celularity A Stock
Celularity A
SupplierCustomer-0,35-0,84-0,91-0,620,140,39
Mabpharm Stock
Mabpharm
SupplierCustomer-0,70 0,610,770,800,58
1

Most common questions regarding Sorrento Therapeutics

What values and corporate philosophy does Sorrento Therapeutics represent?

Sorrento Therapeutics Inc represents values of innovation, excellence, and patient-centered care. With a strong corporate philosophy, the company strives to revolutionize treatment options and improve the lives of patients worldwide. Sorrento Therapeutics Inc is committed to developing cutting-edge therapies, leveraging its expertise in areas such as oncology, immuno-oncology, and neurology. The company's relentless pursuit of scientific advancements drives their commitment to finding new and effective solutions to challenging medical conditions. By prioritizing patient needs and constantly pushing boundaries, Sorrento Therapeutics Inc aims to become a global leader in the healthcare industry.

In which countries and regions is Sorrento Therapeutics primarily present?

Sorrento Therapeutics Inc primarily operates in the United States.

What significant milestones has the company Sorrento Therapeutics achieved?

Sorrento Therapeutics Inc has achieved several significant milestones. The company successfully developed and launched numerous innovative therapies and treatments, establishing itself as a leader in the biopharmaceutical industry. Sorrento Therapeutics Inc received FDA approval for several of its drugs, such as ZTlido and Cynviloq, providing patients with advanced and effective solutions. The company also entered into strategic partnerships and collaborations with renowned organizations, leading to valuable research advancements and increased market presence. Sorrento Therapeutics Inc's commitment to developing cutting-edge treatments, obtaining regulatory approvals, and fostering collaborations have contributed to its remarkable success and growth in the biotech sector.

What is the history and background of the company Sorrento Therapeutics?

Sorrento Therapeutics Inc. is a biopharmaceutical company that specializes in the development of innovative therapies for various medical conditions. Established in 2006, Sorrento Therapeutics Inc. has since emerged as a leading player in the pharmaceutical industry, striving to provide cutting-edge solutions to unmet medical needs. With a strong focus on research and development, the company has built a diverse pipeline of potential treatments, including therapies for cancer, autoimmune diseases, inflammation, and pain. Sorrento Therapeutics Inc. continuously invests in advancing its scientific capabilities and forging strategic partnerships to accelerate the availability of impactful treatments for patients worldwide.

Who are the main competitors of Sorrento Therapeutics in the market?

The main competitors of Sorrento Therapeutics Inc in the market include Amgen Inc., Bristol-Myers Squibb Company, and Merck & Co. These companies are well-established players in the biopharmaceutical industry and offer a range of products and therapies that may compete with or be similar to Sorrento's offerings. It is important for Sorrento to distinguish itself through its unique product portfolio, innovation, and commitment to research and development to stay competitive in this dynamic market.

In which industries is Sorrento Therapeutics primarily active?

Sorrento Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Sorrento Therapeutics?

The business model of Sorrento Therapeutics Inc revolves around developing and commercializing innovative therapies for various medical conditions. With a focus on targeted cancer therapies, Sorrento Therapeutics utilizes its proprietary technologies to develop a diverse pipeline of potential treatments. The company aims to improve patient outcomes by leveraging its expertise in antibody-based therapies, cell therapies, and small molecule drugs. Sorrento Therapeutics emphasizes collaborations and strategic partnerships to advance its research and development efforts. By harnessing its innovative solutions and partnerships, Sorrento Therapeutics Inc strives to make a meaningful impact on global healthcare.

What is the P/E ratio of Sorrento Therapeutics 2025?

The P/E ratio cannot be calculated for Sorrento Therapeutics at the moment.

What is the P/S ratio of Sorrento Therapeutics 2025?

The P/S cannot be calculated for Sorrento Therapeutics currently.

What is the Quality Investing of Sorrento Therapeutics?

The Quality Investing for Sorrento Therapeutics is 6/10.

What is the revenue of Sorrento Therapeutics 2025?

The expected Sorrento Therapeutics revenue is 416.02 M USD.

How high is the profit of Sorrento Therapeutics 2025?

The expected Sorrento Therapeutics profit is 34.21 M USD.

What is the business model of Sorrento Therapeutics

Sorrento Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative treatment options for cancer, pain, and inflammation. The company follows a diversified business model, focusing on various sectors including biopharmaceutical development programs, partnerships and licenses, and medical services. One of the company's main sources of revenue lies in its biopharmaceutical development department. Sorrento Therapeutics is currently developing a range of innovative therapies for cancer, pain, and inflammation. This includes several targeted antibody-drug conjugates (ADCs) specifically targeting cancer cells without affecting healthy cells in the body. The company is also developing a range of pain therapeutics, including tamper-resistant opioid analgesics aiming for increased efficacy and reduced abuse potential in the opioid market. Sorrento Therapeutics also pursues a business model that involves out-licensing and partnerships with other biopharmaceutical companies. These partnerships allow the company to expedite the delivery of its treatments to the market as well as the marketing and distribution. The company has already secured several licenses and partnerships with established players in the biopharmaceutical industry, including collaboration with Celularity in 2019 to include mesenchymal stem cells in their COV-X™ technology program for the treatment of COVID-19. In addition to its biopharmaceutical activities, Sorrento Therapeutics also operates a range of service offerings in personalized medicine. The company has developed a proprietary diagnostic platform called CGuardTM, which enables the identification of potential cancer types by analyzing the tumor microenvironment. CGuard is designed to inform and provide oncologists with individually tailored treatment options for each patient. In summary, Sorrento Therapeutics, Inc. follows a diverse and innovative business model based on the development and commercialization of innovative cancer, pain, and inflammation therapeutics, partnerships and licenses, as well as diagnostic services in the field of personalized medicine. With its range of activities and comprehensive solutions, the company is well-positioned and protected, with good prospects of establishing itself as a leading company in the biopharmaceutical industry.

What is the Sorrento Therapeutics dividend?

Sorrento Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Sorrento Therapeutics pay dividends?

The dividend cannot currently be calculated for Sorrento Therapeutics or the company does not pay out a dividend.

What is the Sorrento Therapeutics ISIN?

The ISIN of Sorrento Therapeutics is US83587F2020.

What is the Sorrento Therapeutics WKN?

The WKN of Sorrento Therapeutics is A1W8DY.

What is the Sorrento Therapeutics ticker?

The ticker of Sorrento Therapeutics is SRNE.

How much dividend does Sorrento Therapeutics pay?

Over the past 12 months, Sorrento Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sorrento Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Sorrento Therapeutics?

The current dividend yield of Sorrento Therapeutics is .

When does Sorrento Therapeutics pay dividends?

Sorrento Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sorrento Therapeutics?

Sorrento Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Sorrento Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sorrento Therapeutics located?

Sorrento Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sorrento Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sorrento Therapeutics from 9/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.

When did Sorrento Therapeutics pay the last dividend?

The last dividend was paid out on 9/26/2025.

What was the dividend of Sorrento Therapeutics in the year 2024?

In the year 2024, Sorrento Therapeutics distributed 0 USD as dividends.

In which currency does Sorrento Therapeutics pay out the dividend?

The dividends of Sorrento Therapeutics are distributed in USD.

All fundamentals about Sorrento Therapeutics

Our stock analysis for Sorrento Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sorrento Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.